GlassScriptPhysician profile
Lorraine Nombrano
NPI 1043827256
$1,389.11
in general payments reported to CMS, 2019-2025
13 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $147 · 2022: $346 · 2023: $635 · 2024: $145 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $797 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $797.13 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $450.64 | 2022-2025 | |
| Janssen Biotech, INC. | $168.80 | 2021-2023 | Symtuza, Prezcobix |
| Viiv Healthcare Company | $141.59 | 2022-2024 | Rukobia, Cabenuva |
| Merck Sharp & Dohme LLC | $123.44 | 2022-2023 | Delstrigo, Dificid, Zerbaxa |
| Ferring Pharmaceuticals INC. | $115.40 | 2022-2023 | Rebyota |
| Astellas Pharma US INC | $99.00 | 2023 | |
| Shionogi INC | $80.34 | 2021-2023 | Fetroja |
| Gilead Sciences, INC. | $50.86 | 2021-2022 | |
| La Jolla Pharmaceutical Company | $47.31 | 2021 | |
| Melinta Therapeutics, LLC | $33.37 | 2021-2023 | Vabomere, Kimyrsa |
| Cumberland Pharmaceuticals, INC. | $33.30 | 2023 | Vibativ |
| Paratek Pharmaceuticals, INC. | $22.86 | 2025 | Nuzyra |
| Takeda Pharmaceuticals U.S.A., INC. | $22.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorraine Nombrano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.